Truist Reiterates Buy Rating for Viridian Therapeutics (VRDN) [Yahoo! Finance]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
On April 21, Truist reduced the price target on Viridian Therapeutics Inc. (NASDAQ:VRDN) from $36 to $33 while maintaining a Buy rating on the stock. Despite the downward revision in target price, the stock still offers an attractive upside potential of more than 140%, making it one of the best oversold small-cap names. Likoper/Shutterstock.com The firm is modifying its model based on revised assumptions around volume and pricing, keeping in mind a possible launch of Veli for both acute and chronic thyroid eye disease. It continues to hold positive sentiment towards the stock due to the visible catalysts ahead. On April 8, Laura Chico from Wedbush maintained an Outperform rating for Viridian Therapeutics Inc. (NASDAQ:VRDN) while reducing the target price from $37 to $31. The analyst noted that over the past several years, the company has effectively managed a number of competitive threats in the industry. However, Chico cautions that, in light of a recent pipeline update from
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics (VRDN) Stock Posts Double-Digit Growth Year-on-Year [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics (VRDN) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics (VRDN) had its price target lowered by Truist Financial Corporation from $36.00 to $33.00. They now have a "buy" rating on the stock.MarketBeat
- Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 20% [Yahoo! Finance]Yahoo! Finance
VRDN
Earnings
- 2/26/26 - Miss
VRDN
Sec Filings
- 4/17/26 - Form ARS
- 4/17/26 - Form DEFA14A
- 4/17/26 - Form DEF
- VRDN's page on the SEC website